Linked Life Data

12941420

Source:http://linkedlifedata.com/resource/pubmed/id/12941420

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2003-8-27
pubmed:abstractText
New insights have been gained into the therapeutic relevance of the sphingosine 1-phosphate (S1P) pathway, on the basis of reverse pharmacological approaches to defining the mechanism of action of the immunosuppressive agent FTY720. Natural and synthetic sphingosine 1-phosphate receptor agonists can make picomolar interactions with their cognate G-protein-coupled receptors, and provide chemical approaches to defining the contribution of distinct receptor subtypes to pathology, physiology and treatment. The chemistry of S1P receptors and their synthetic ligands present a paradigm for the understanding of lipid-receptor interactions and their contribution to physiology and pathology. These approaches can potentially be extended to a broad, related family of G-protein-coupled receptors that share ligands and ligand similarities.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1367-5931
pubmed:author
pubmed:issnType
Print
pubmed:volume
7
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
461-8
pubmed:dateRevised
2009-8-25
pubmed:meshHeading
pubmed:year
2003
pubmed:articleTitle
Sphingosine 1-phosphate pathway therapeutics: a lipid ligand-receptor paradigm.
pubmed:affiliation
Department of Immunology and Committee for Advanced Human Therapeutics, The Scripps Research Institute, ICND-118 10550 North Torrey Pines Road, La Jolla, CA 92037, USA. hrosen@scripps.edu
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't